BioWorld

Sep. 29, 2003

View Archived Issues

Novogen Cancer Subsidiary Files IPO, Seeks Up To $13M

Chromosome 15's 4 Mutant Genes Focus Hotspots For Derangements In Michigan, Penn Research Centers

Hollis-Eden Raises $62.5M; This Time In Public Offering

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Appointments And Advancements

Other News To Note

After Phase II Miss, HGS Stops Repifermin Venous Ulcers Work

Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Feb. 9, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...